BioSpace News Archive

TransCode Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company’s Investigational New Drug (IND) application and concluded that the company may proceed with its Phase 1/2 multicenter, open-label, dose-escalation and dose-expansion study of its lead therapeutic candidate.

Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH ) announces the purchase of four technologies for production of three generic drugs in tablet form and one dietary supplement.

Genentech, a member of the Roche Group, announced the Phase III STARGLO study met its primary endpoint of overall survival.

BC Platforms, a global leader in real world data, healthcare data management, and analytics, announces an exclusive collaboration with NTT Life Science Corporation, a company in the medical field of the NTT Group, to accelerate data-driven medicine.

BioBam, a leading provider of bioinformatics solutions, is pleased to announce the launch of OmicsBox 3.2 at the BIO-IT World Expo in Boston.

Aurinia Pharmaceuticals Inc. announced that it will release financial and operational results for the first quarter of 2024 on Thursday, May 2, 2024, before markets open.

Kraig Biocraft Laboratories, Inc., announces that the spring production trials for the new BAM-1 hybrid have begun and are well on track to meet the Company’s expectations and timeline.

Applied Therapeutics, Inc. announced the appointment of Dale Hooks as Chief Commercial Officer, replacing Adam Hansard, effective immediately.

Pulmocide Ltd. today announced topline results from the OPERA-S study: a Phase 2 safety and tolerability study in lung transplant patients receiving inhaled opelconazole monotherapy as prophylaxis against pulmonary aspergillosis.

Viatris Inc. today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company’s Executive Leadership Team, effective today.